Humanized mouse models of HIV-1 latency

Current HIV Research

Volumn 9, Issue 8, 2011, Pages 595-605

  Duyne, Rachel V ^a,b   Narayanan, Aarthi ^a   Hall, Kylene K ^a   Saifuddin, Mohammed ^c   Shultz, Leonard ^d   Kashanchi, Fatah ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d JACKSON LABORATORY   (United States)

Author keywords

HAART; HIV 1; Humanized mouse model; Latency

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD34 ANTIGEN; CD4 ANTIGEN; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROFILAMENT PROTEIN; NEUROTOXIN; PROTEIN BCL 2; STAPHYLOCOCCUS ENTEROTOXIN B; SYNAPTOPHYSIN; TENOFOVIR; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTING CELL; APOPTOSIS; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL LINEAGE; CELL PROLIFERATION; CELL TRANSFORMATION; CEREBROSPINAL FLUID; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIFFUSION TENSOR IMAGING; DISEASE CARRIER; DISEASE CLASSIFICATION; DISEASE MODEL; ENCEPHALITIS; ENTEROPATHY; GENE EXPRESSION; GENE MUTATION; GENITAL SYSTEM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE LYMPHATIC TISSUE; LIVER; LYMPHOID TISSUE; MACACA FASCICULARIS; MACACA MULATTA; MACACA NEMESTRINA; MACROPHAGE; MICROGLIA; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NERVOUS SYSTEM; PHAGOCYTE; PRIMATE; REVIEW; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; THYMUS; VIREMIA; VIRION; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MICE; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84856447006     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798998781     Document Type: Review

References (120)

1. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61(2): 213-22.
2. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reversetranscribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992; 66(3): 1717-25.
3. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991; 254(5030): 423-7.
4. Pierson TC, Zhou Y, Kieffer TL, et al. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002; 76(17): 8518-31.
5. Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep 2010; 7(1): 37-43.
6. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5(5): 512-7.
7. Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 2008; 8: 2.
8. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387(6629): 183-8.
9. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007; 5(2): 95-106.
10. Yang HC. Primary cell models of HIV latency. Curr Opin HIV AIDS 2011; 6(1): 62-7.
11. Verdin E, Jordan A, Bisgrove D. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 2003; 22(8): 1868-77.
12. Williams SA, Chen LF, Kwon H, et al. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J 2006; 25(1): 139-49.
13. Mahmoudi T, Parra M, Vries RG, et al. The SWI/SNF chromatinremodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem 2006; 281(29): 19960-8.
14. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 2003; 22(8): 1868-77.
15. Han Y, Lassen K, Monie D, et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004; 78(12): 6122-33.
16. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110(4): 521-9.
17. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300(5626): 1749-51.
18. Liu H, Dow EC, Arora R, et al. Integration of human immunodeficiency virus type 1 in untreated infection occurs preferentially within genes. J Virol 2006; 80(15): 7765-8.
19. Lewinski MK, Bisgrove D, Shinn P, et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol 2005; 79(11): 6610-9.
20. Kim YK, Bourgeois CF, Pearson R, et al. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. Embo J 2006; 25(15): 3596-604.
21. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 2005; 122(2): 169-82.
22. Marini A, Harper JM, Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 2008; 181(11): 7713-20.
23. Sahu GK, Lee K, Ji J, et al. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ Tlymphocytes. Virology 2006; 355(2): 127-37.
24. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010; 84(13): 6425-37.
25. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009; 113(1): 58-65.
26. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119(11): 3473-86.
27. Agosto LM, Yu JJ, Dai J, et al. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 2007; 368(1): 60-72.
28. Swiggard WJ, Baytop C, Yu JJ, et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 2005; 79(22): 14179-88.
29. Dai J, Agosto LM, Baytop C, et al. Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol 2009; 83(9): 4528-37.
30. Van Rompay KK. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res 2010; 85(1): 159-75.
31. Deere JD, Schinazi RF, North TW. Simian immunodeficiency virus macaque models of HIV latency. Curr Opin HIV AIDS 2011; 6(1): 57-61.
32. Shen A, Zink MC, Mankowski JL, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003; 77(8): 4938-49.
33. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83(18): 9247-57.
34. Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 2010; 202(1): 161-70.
35. Annamalai L, Bhaskar V, Pauley DR, et al. Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques. Am J Pathol 2010; 177(2): 777-91.
36. Marcondes MC, Flynn C, Huitron-Rezendiz S, et al. Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virusinfected rhesus monkeys. AIDS 2009; 23(10): 1187-95.
37. Bieniasz PD, Cullen BR. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol 2000; 74(21): 9868-77.
38. Zhang JX, Diehl GE, Littman DR. Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS One 2008; 3(4): e2035.
39. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983; 301(5900): 527-30.
40. Van Duyne R, Pedati C, Guendel I, et al. The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 2009; 6: 76.
41. Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem cell engraftment. Stem Cells 1998; 16(3): 166-77.
42. McCune JM, Namikawa R, Kaneshima H, et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241(4873): 1632-9.
43. McCune J, Kaneshima H, Krowka J, et al. The SCID-hu mouse: a small animal model for HIV infection and pathogenesis. Annu Rev Immunol 1991; 9: 399-429.
44. McCune JM. Development and applications of the SCID-hu mouse model. Semin Immunol 1996; 8(4): 187-96.
45. Tary-Lehmann M, Saxon A. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J Exp Med 1992; 175(2): 503-16.
46. Hoffmann-Fezer G, Gall C, Zengerle U, Kranz B, Thierfelder S. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 1993; 81(12): 3440-8.
47. Reinhardt B, Torbett BE, Gulizia RJ, et al. Human immunodeficiency virus type 1 infection of neonatal severe combined immunodeficient mice xenografted with human cord blood cells. AIDS Res Hum Retroviruses 1994; 10(2): 131-41.
48. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSzscid mice. J Immunol 1995; 154(1): 180-91.
49. Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003; 18(1): 41-51.
50. Baxter AG, Cooke A. Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes 1993; 42(11): 1574-8.
51. Pearson T, Greiner DL, Shultz LD. Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol 2008; 324: 25-51.
52. Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005; 106(5): 1565-73.
53. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100(9): 3175-82.
54. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174(10): 6477-89.
55. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304(5667): 104-7.
56. Goldman J. Julie Goldman. The New Jersey medicine interview. Interview by Bill Berlin. N J Med 1998; 95(9): 55-6.
57. Mazurier F, Fontanellas A, Salesse S, et al. A novel immunodeficient mouse model--RAG2 x common cytokine receptor gamma chain double mutants--requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J Interferon Cytokine Res 1999; 19(5): 533-41.
58. Berges BK, Rowan MR. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 2011; 8: 65.
59. Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. Virology 2011; 411(2): 344-54.
60. Iglesias-Ussel MD, Romerio F. HIV reservoirs: the new frontier. AIDS Rev 2011; 13(1): 13-29.
61. Stevenson M. HIV-1 pathogenesis. Nat Med 2003; 9(7): 853-60.
62. Folks TM, Kessler SW, Orenstein JM, et al. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988; 242(4880): 919-22.
63. Stanley SK, Kessler SW, Justement JS, et al. CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992; 149(2): 689-97.
64. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010; 16(4): 446-51.
65. McNamara LA, Collins KL. Hematopoietic stem/precursor cells as HIV reservoirs. Curr Opin HIV AIDS 2011; 6(1): 43-8.
66. Bannert N, Farzan M, Friend DS, et al. Human Mast cell progenitors can be infected by macrophagetropic human immunodeficiency virus type 1 and retain virus with maturation in vitro. J Virol 2001; 75(22): 10808-14.
67. Smith BA, Gartner S, Liu Y, et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol 2001; 166(1): 690-6.
68. Lambotte O, Deiva K, Tardieu M. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol 2003; 13(1): 95-103.
69. Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 2011; 31(26): 9456-65.
70. Carroll-Anzinger D, Kumar A, Adarichev V, Kashanchi F, Al-Harthi L. Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway. J Virol 2007; 81(11): 5864-71.
71. Henderson LJ, Al-Harthi L. Role of beta-catenin/TCF-4 signaling in HIV replication and pathogenesis: insights to informing novel anti-HIV molecular therapeutics. J Neuroimmune Pharmacol 2011; 6(2): 247-59.
72. Berges BK, Akkina SR, Remling L, Akkina R. Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 2010; 397(1): 100-3.
73. An DS, Poon B, Ho Tsong Fang R, et al. Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2007; 14(4): 391-6.
74. Baenziger S, Tussiwand R, Schlaepfer E, et al. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/-mice. Proc Natl Acad Sci U S A 2006; 103(43): 15951-6.
75. Brainard DM, Seung E, Frahm N, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009; 83(14): 7305-21.
76. Gorantla S, Makarov E, Finke-Dwyer J, et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol 2010; 177(6): 2938-49.
77. Kuruvilla JG, Troyer RM, Devi S, Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology 2007; 369(1): 143-52.
78. Melkus MW, Estes JD, Padgett-Thomas A, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006; 12(11): 1316-22.
79. Tonomura N, Habiro K, Shimizu A, Sykes M, Yang YG. Antigenspecific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood 2008; 111(8): 4293-6.
80. Watanabe S, Terashima K, Ohta S, et al. Hematopoietic stem cellengrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 2007; 109(1): 212-8.
81. Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/-(RAG-hu) mouse model. Retrovirology 2006; 3: 76.
82. Denton PW, Garcia JV. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep 2009; 6(1): 13-9.
83. Koyanagi Y, Tanaka Y, Ito M, Yamamoto N. Humanized mice for human retrovirus infection. Curr Top Microbiol Immunol 2008; 324: 133-48.
84. Aldrovandi GM, Feuer G, Gao L, et al. The SCID-hu mouse as a model for HIV-1 infection. Nature 1993; 363(6431): 732-6.
85. Bonyhadi ML, Rabin L, Salimi S, et al. HIV induces thymus depletion in vivo. Nature 1993; 363(6431): 728-32.
86. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA. Generation of HIV latency during thymopoiesis. Nat Med 2001; 7(4): 459-64.
87. Krowka JF, Sarin S, Namikawa R, McCune JM, Kaneshima H. Human T cells in the SCID-hu mouse are phenotypically normal and functionally competent. J Immunol 1991; 146(11): 3751-6.
88. Brooks DG, Arlen PA, Gao L, Kitchen CM, Zack JA. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A 2003; 100(22): 12955-60.
89. Brooks DG, Hamer DH, Arlen PA, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003; 19(3): 413-23.
90. Choudhary S, Archin N, Cheema M, et al. Latent HIV-1 Infection of Resting CD4+ T Cells in the Humanized Rag2-/-{gamma}c-/-Mouse. J Virol 2011.
91. Denton PW, Olesen R, Choudhary SK, et al. Generation of HIV Latency in BLT Humanized Mice. J Virol 2011.
92. Yao H, Bethel-Brown C, Li CZ, Buch SJ. HIV neuropathogenesis: a tight rope walk of innate immunity. J Neuroimmune Pharmacol 2010; 5(4): 489-95.
93. Dash PK, Gorantla S, Gendelman HE, et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci 2011; 31(9): 3148-57.
94. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197(5): 714-20.
95. Sun Z, Denton PW, Estes JD, et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007; 204(4): 705-14.
96. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5(1): e16.
97. Olesen R, Wahl A, Denton PW, Garcia JV. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol 2011; 88(2): 195-203.
98. Denton PW, Krisko JF, Powell DA, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 2010; 5(1): e8829.
99. Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006; 108(2): 487-92.
100. Rajesh D, Zhou Y, Jankowska-Gan E, et al. Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol 2010; 71(6): 551-9.
101. Denton PW, Othieno F, Martinez-Torres F, et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011; 85(15): 7582-93.
102. Akkina R, Berges BK, Palmer BE, et al. Humanized Rag1-/-gammac-/-mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routes. PLoS One 2011; 6(6): e20169.
103. Berges BK, Akkina SR, Folkvord JM, Connick E, Akkina R. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/-gammac-/-(RAG-hu) mice. Virology 2008; 373(2): 342-51.
104. Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 2011; 6(6): e20209.
105. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R. Oral preexposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010; 5(12): e15257.
106. Emiliani S, Fischle W, Ott M, et al. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol 1998; 72(2): 1666-70.
107. Emiliani S, Van Lint C, Fischle W, et al. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A 1996; 93(13): 6377-81.
108. Clements JE, Mankowski JL, Gama L, Zink MC. The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol 2008; 14(4): 309-17.
109. Zink MC, Laast VA, Helke KL, et al. From mice to macaques--animal models of HIV nervous system disease. Curr HIV Res 2006; 4(3): 293-305.
110. Choudhary SK, Rezk NL, Ince WL, et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/-mouse. J Virol 2009; 83(16): 8254-8.
111. Sango K, Joseph A, Patel M, et al. Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/-mice. AIDS Res Hum Retroviruses 2010; 26(7): 735-46.
112. Mulloy JC, Wunderlich M, Zheng Y, Wei J. Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling. Cell Cycle 2008; 7(21): 3314-9.
113. Wunderlich M, Chou FS, Link KA, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 2010; 24(10): 1785-8.
114. Billerbeck E, Barry WT, Mu K, et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 2011; 117(11): 3076-86.
115. Legrand N, Ploss A, Balling R, et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 2009; 6(1): 5-9.
116. Manz MG. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 2007; 26(5): 537-41.
117. Legrand N, Weijer K, Spits H. Experimental models to study development and function of the human immune system in vivo. J Immunol 2006; 176(4): 2053-8.
118. Chen Q, Khoury M, Chen J. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A 2009; 106(51): 21783-8.
119. Kwant-Mitchell A, Pek EA, Rosenthal KL, Ashkar AA. Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge. PLoS One 2009; 4(12): e8379.
120. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9(3): 239-44.